Navigating Trade-Offs Between Surrogates & Clinical Endpoints in Relation to Generalizability

Time: 12:00 pm
day: Day 1 Track 3 AM


  • Highlighting how treatment effects on a clinical endpoint may reflect a relatively small subgroup of the trial population
  • Contrasting how surrogate endpoints such as GFR slope can be evaluated in the full trial population
  • Addressing the tradeoffs between having of a more definitive of benefit vs. a broader evaluation across the trial population for clinical and surrogate endpoints